BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) - Northland Capmk reduced their Q4 2024 earnings per share estimates for shares of BioLife Solutions in a note issued to investors on Wednesday, January 8th. Northland Capmk analyst C. Byrnes now anticipates that the medical equipment provider will earn ($0.04) per share for the quarter, down from their prior estimate of ($0.01). The consensus estimate for BioLife Solutions' current full-year earnings is ($0.29) per share. Northland Capmk also issued estimates for BioLife Solutions' Q1 2025 earnings at ($0.03) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.05) EPS.
Other analysts have also recently issued reports about the stock. TD Cowen boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. KeyCorp upped their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. HC Wainwright decreased their target price on BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a report on Monday, November 18th. Benchmark reissued a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, Northland Securities lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an "outperform" rating in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions presently has an average rating of "Moderate Buy" and a consensus target price of $29.43.
Check Out Our Latest Research Report on BLFS
BioLife Solutions Trading Up 0.5 %
Shares of BLFS stock traded up $0.14 during trading hours on Monday, hitting $26.75. 159,326 shares of the company were exchanged, compared to its average volume of 206,986. BioLife Solutions has a 1 year low of $14.50 and a 1 year high of $28.88. The firm has a fifty day moving average of $26.04 and a 200 day moving average of $24.37. The firm has a market cap of $1.24 billion, a PE ratio of -25.24 and a beta of 1.92. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.
Insider Transactions at BioLife Solutions
In other BioLife Solutions news, EVP Aby J. Mathew sold 25,000 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the completion of the transaction, the executive vice president now directly owns 302,046 shares of the company's stock, valued at approximately $6,394,313.82. This trade represents a 7.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Greef Roderick De sold 46,896 shares of the business's stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $23.43, for a total value of $1,098,773.28. Following the completion of the sale, the chief executive officer now directly owns 414,958 shares in the company, valued at $9,722,465.94. This represents a 10.15 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 113,129 shares of company stock worth $2,576,818. Company insiders own 2.20% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of BLFS. Mark Sheptoff Financial Planning LLC acquired a new position in shares of BioLife Solutions in the third quarter worth about $28,000. Quest Partners LLC purchased a new stake in shares of BioLife Solutions in the 3rd quarter valued at approximately $57,000. GAMMA Investing LLC boosted its stake in BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock worth $83,000 after purchasing an additional 748 shares during the period. Canada Pension Plan Investment Board acquired a new position in BioLife Solutions in the 2nd quarter worth approximately $122,000. Finally, Arizona State Retirement System purchased a new position in BioLife Solutions during the 2nd quarter worth approximately $217,000. Institutional investors own 93.24% of the company's stock.
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Stories
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
